Article Information
PubMed
Published By
History
- Received August 24, 2022
- Revision received March 16, 2023
- Accepted March 28, 2023
- Published online May 4, 2023.
Copyright & Usage
Copyright © 2023 Russo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Author Information
Author contributions
Author contributions: E.E.R., L.E.Z., R.N., A.J.R., and A.S. designed research; E.E.R., L.E.Z., R.N., H.S., A.J.R., and A.S. performed research; R.N. contributed unpublished reagents/analytic tools; E.E.R., L.E.Z., R.N., A.J.R., and A.S. analyzed data; E.E.R. and L.E.Z. wrote the paper.
↵* E.E.R. and L.E.Z. contributed equally to this work.
Disclosures
The authors declare no competing financial interests.
This work was supported by Canadian Institutes of Health Research (CHIR) Grants 391676 and 407961 (to A.S.).
Funding
Canadian Institutes of Health Research (CIHR)
391676; 407961
Article usage
In this issue
Evaluation and Validation of Commercially Available Dopamine Transporter Antibodies
